相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FRI0245 Prospective follow-up of tocilizumab treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data from the french registry regate (registry –roactemra)
J. Morel et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Proposal for a new nomenclature of disease-modifying antirheumatic drugs
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
Cecile Gaujoux-Viala et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
Jackie L. Nam et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients
Takao Koike et al.
Modern Rheumatology (2014)
Tofacitinib for Treatment of Rheumatoid Arthritis
Chadi Rakieh et al.
ADVANCES IN THERAPY (2013)
Initiation of Anti-TNF Therapy and the Risk of Optic Neuritis: From the Safety Assessment of Biologic ThERapy (SABER) Study
Kevin L. Winthrop et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2013)
Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
James B. Galloway et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Mycobacterial diseases and antitumour necrosis factor therapy in USA
K. L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases
N. Duru et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Tumor necrosis factor a inhibitor therapy and cancer risk in chronic immune-mediated diseases
Kevin Haynes et al.
ARTHRITIS AND RHEUMATISM (2013)
Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry
Pavel Horak et al.
CLINICAL RHEUMATOLOGY (2013)
Association Between the Initiation of Anti-Tumor Necrosis Factor Therapy and the Risk of Herpes Zoster
Kevin L. Winthrop et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population
Louise K. Mercer et al.
RHEUMATOLOGY (2013)
Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis
Y. Hishitani et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2013)
Safety of Surgery After Rituximab Therapy in 133 Patients With Rheumatoid Arthritis: Data From the AutoImmunity and Rituximab Registry
S. Godot et al.
ARTHRITIS CARE & RESEARCH (2013)
Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden
Pauline Raaschou et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register
Louise K. Mercer et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study
Elizabeth V. Arkema et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis
Lotta Ljung et al.
ARTHRITIS AND RHEUMATISM (2012)
Mortality Rates in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors Drug-Specific Comparisons in the Swedish Biologics Register
Julia F. Simard et al.
ARTHRITIS AND RHEUMATISM (2012)
Association between anti-TNF-a therapy and all-cause mortality
Lisa J. Herrinton et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
Risk of Mortality, Fatal Infection, and Fatal Malignancy Related to Use of Anti-Tumor Necrosis Factor-α Biologics by Rheumatoid Arthritis Patients
Veena Thyagarajan et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2012)
Risk of Significant Infection in Rheumatoid Arthritis Patients Switching Anti-Tumor Necrosis Factor-α Drugs
Bao-Anh Nguyen-Khoa et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2012)
Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis
Jeffrey R. Curtis et al.
ARTHRITIS CARE & RESEARCH (2012)
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis
Jeffrey D. Greenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents
Jeffrey R. Curtis et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register
Rebecca Davies et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study
W. G. Dixon et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register
J. B. Galloway et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
A. Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
Takao Koike et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
The Incidence of Gastrointestinal Perforations Among Rheumatoid Arthritis Patients
Jeffrey R. Curtis et al.
ARTHRITIS AND RHEUMATISM (2011)
Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
Carlos G. Grijalva et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety
Yukiko Komano et al.
JOURNAL OF RHEUMATOLOGY (2011)
TNF-α Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans With Rheumatoid Arthritis
Michael A. Lane et al.
MEDICINE (2011)
Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers
Anja Strangfeld et al.
RHEUMATOLOGY (2011)
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
James B. Galloway et al.
RHEUMATOLOGY (2011)
Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis
Wassila Amari et al.
RHEUMATOLOGY (2011)
The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
James B. Galloway et al.
RHEUMATOLOGY (2011)
Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists
Loreto Carmona et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2011)
Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry
X. Mariette et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry
J. D. Greenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Demyelinating events in rheumatoid arthritis after drug exposures
Sasha Bernatsky et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
W. G. Dixon et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists
Ignacio Garcia-Doval et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis
Jeremy Sokolove et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register
W. G. Dixon et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology
William G. Dixon et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
No Evidence of Association Between Anti-Tumor Necrosis Factor Treatment and Mortality in Patients With Rheumatoid Arthritis Results From the British Society for Rheumatology Biologics Register
Mark Lunt et al.
ARTHRITIS AND RHEUMATISM (2010)
Risk Factors for Severe Infections in Patients With Rheumatoid Arthritis Treated With Rituximab in the AutoImmunity and Rituximab Registry
J. -E. Gottenberg et al.
ARTHRITIS AND RHEUMATISM (2010)
Tumour necrosis factor antagonist therapy and cancer development: Analysis of the LORHEN registry
Francesca Bobbio Pallavicini et al.
AUTOIMMUNITY REVIEWS (2010)
Initiation of rheumatoid arthritis treatments and the risk of serious infections
Carlos G. Grijalva et al.
RHEUMATOLOGY (2010)
Influence of Anti-Tumor Necrosis Factor Therapy on Cancer Incidence in Patients With Rheumatoid Arthritis Who Have Had a Prior Malignancy: Results From the British Society for Rheumatology Biologics Register
W. G. Dixon et al.
ARTHRITIS CARE & RESEARCH (2010)
Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT
Anja Strangfeld et al.
ARTHRITIS RESEARCH & THERAPY (2010)
European biologicals registers: methodology, selected results and perspectives
A. Zink et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
J. Askling et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register
M. J. Harrison et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Rheumatoid Arthritis, Its Treatments, and the Risk of Tuberculosis in Quebec, Canada
Paul Brassard et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Cancer Risk in Patients With Rheumatoid Arthritis Treated With Anti-Tumor Necrosis Factor α Therapies Does the Risk Change With the Time Since Start of Treatment?
Johan Askling et al.
ARTHRITIS AND RHEUMATISM (2009)
Risk of Tuberculosis Is Higher With Anti-Tumor Necrosis Factor Monoclonal Antibody Therapy Than With Soluble Tumor Necrosis Factor Receptor Therapy The Three-Year Prospective French Research Axed on Tolerance of Biotherapies Registry
F. Tubach et al.
ARTHRITIS AND RHEUMATISM (2009)
Herpes Zoster Risk Factors in a National Cohort of Veterans with Rheumatoid Arthritis
Jay R. McDonald et al.
CLINICAL INFECTIOUS DISEASES (2009)
Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti-TNF-α Agents
Anja Strangfeld et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan
Takao Koike et al.
JOURNAL OF RHEUMATOLOGY (2009)
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
J. N. Hoes et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Evaluation of the quality of prognosis studies in systematic reviews
JA Hayden et al.
ANNALS OF INTERNAL MEDICINE (2006)
Safety of low dose glucocorticoid treatment in rheumatoid arthritis:: published evidence and prospective trial data
JAP Da Silva et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Predictors of infection in rheumatoid arthritis
MF Doran et al.
ARTHRITIS AND RHEUMATISM (2002)
分享论文
